Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658995 · ClinicalTrials.gov registry record · Phase 3
Management of Etonogestrel Subdermal Implant-related Bleeding
A Phase 3 study of ESI-related Bleeding, sponsored by Petra M. Casey.
- Completed
- Registry status
- Phase 3
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT01658995: Completed Phase 3 study of ESI-related Bleeding, sponsored by Petra M. Casey.
NCT01658995 is a Phase 3 study of ESI-related Bleeding that has completed, run by Petra M. Casey. The registered enrollment target is 82 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01658995, a Phase 3 study of ESI-related Bleeding, has completed, sponsored by Petra M. Casey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.
Primary Outcome
The proportion of subjects who requested additional secondary treatment of intervention after ESI
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Doxycycline
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2012-09-13 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 3 |
What the finished NCT01658995 record still lists
NCT01658995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with ESI-related Bleeding appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01658995 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01658995 about?
NCT01658995 is a clinical study titled "Management of Etonogestrel Subdermal Implant-related Bleeding". This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleed...
What is the current status of trial NCT01658995?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 82 participants. The study started on 2012-09-13. Estimated completion is 2019-12-30.
What conditions does trial NCT01658995 study?
This clinical trial studies the following conditions: ESI-related Bleeding.
What interventions are being tested in trial NCT01658995?
The interventions under investigation include: Placebo (DRUG), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01658995?
This trial is sponsored by Petra M. Casey, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01658995 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01658995's enrollment target sits among peer trials
82 1752nd of 2000 higher than 249 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI